JP2023554382A - タウ結合化合物 - Google Patents

タウ結合化合物 Download PDF

Info

Publication number
JP2023554382A
JP2023554382A JP2023536348A JP2023536348A JP2023554382A JP 2023554382 A JP2023554382 A JP 2023554382A JP 2023536348 A JP2023536348 A JP 2023536348A JP 2023536348 A JP2023536348 A JP 2023536348A JP 2023554382 A JP2023554382 A JP 2023554382A
Authority
JP
Japan
Prior art keywords
seq
amino acid
antibody
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023536348A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554382A5 (https=
Inventor
クレラ、ビノドバブ
リュー、リー
カバナー、ディロン
ディ． カピリ、アラン
ホウ、ジンジャオ
カーター、トッド
リュー、ウェンチェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Voyager Therapeutics Inc
Original Assignee
Voyager Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voyager Therapeutics Inc filed Critical Voyager Therapeutics Inc
Publication of JP2023554382A publication Critical patent/JP2023554382A/ja
Publication of JP2023554382A5 publication Critical patent/JP2023554382A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023536348A 2020-12-16 2021-12-15 タウ結合化合物 Pending JP2023554382A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126024P 2020-12-16 2020-12-16
US63/126,024 2020-12-16
PCT/US2021/063551 WO2022132923A1 (en) 2020-12-16 2021-12-15 Tau binding compounds

Publications (2)

Publication Number Publication Date
JP2023554382A true JP2023554382A (ja) 2023-12-27
JP2023554382A5 JP2023554382A5 (https=) 2024-12-19

Family

ID=80112434

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536348A Pending JP2023554382A (ja) 2020-12-16 2021-12-15 タウ結合化合物

Country Status (11)

Country Link
US (1) US20240059766A1 (https=)
EP (1) EP4263599A1 (https=)
JP (1) JP2023554382A (https=)
KR (1) KR20230157296A (https=)
CN (1) CN117043183A (https=)
AU (1) AU2021403010A1 (https=)
CA (1) CA3205586A1 (https=)
IL (1) IL303638A (https=)
MX (1) MX2023007181A (https=)
TW (1) TW202239765A (https=)
WO (1) WO2022132923A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
CN121773336A (zh) * 2023-07-20 2026-03-31 拉亚·蒙托柳加亚 P-tau免疫测定
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502141A (ja) * 2010-10-07 2014-01-30 エーシー イミューン エス．エー． タウを認識するリン酸化部位特異的抗体
JP2014531216A (ja) * 2011-10-07 2014-11-27 エーシー イミューン エス．エー． タウを認識するホスホ特異的抗体
WO2019118906A2 (en) * 2017-12-14 2019-06-20 University Of Florida Research Foundation Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
WO1994013795A1 (en) 1992-12-14 1994-06-23 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
EP2319301B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human Ig lambda light chain genes
US7605249B2 (en) 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
AU2009298458B2 (en) 2008-09-30 2015-10-08 Ablexis, Llc Non-human mammals for the production of chimeric antibodies
ES2984483T3 (es) 2010-03-31 2024-10-29 Ablexis Llc Ingeniería genética de ratones para la producción de anticuerpos quiméricos
MX350311B (es) 2011-12-20 2017-09-01 Janssen Biotech Inc Anticuerpos anti-phf-tau y sus usos.
NZ630542A (en) 2012-08-16 2017-06-30 Ipierian Inc Methods of treating a tauopathy
CA2896066C (en) * 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
SG11202008098TA (en) * 2018-03-28 2020-10-29 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502141A (ja) * 2010-10-07 2014-01-30 エーシー イミューン エス．エー． タウを認識するリン酸化部位特異的抗体
JP2014531216A (ja) * 2011-10-07 2014-11-27 エーシー イミューン エス．エー． タウを認識するホスホ特異的抗体
WO2019118906A2 (en) * 2017-12-14 2019-06-20 University Of Florida Research Foundation Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACTA NEUROPATHOL., vol. 103, no. 1, JPN5024007810, 2002, pages 26 - 35, ISSN: 0005723053 *
ACTA NEUROPATHOLOGICA COMMUNICATIONS, vol. 5, no. 58, JPN5024007811, 2017, pages 1 - 11, ISSN: 0005723054 *
MOLECULAR NEURODEGENERATION, vol. 12, no. 87, JPN5024007808, 2017, pages 1 - 19, ISSN: 0005723052 *
NEUROSCIENCE LETTERS, vol. 189, no. 3, JPN5024007809, 1995, pages 167 - 170, ISSN: 0005723051 *

Also Published As

Publication number Publication date
TW202239765A (zh) 2022-10-16
US20240059766A1 (en) 2024-02-22
AU2021403010A9 (en) 2024-09-26
AU2021403010A1 (en) 2023-07-13
WO2022132923A1 (en) 2022-06-23
CN117043183A (zh) 2023-11-10
KR20230157296A (ko) 2023-11-16
IL303638A (en) 2023-08-01
CA3205586A1 (en) 2022-06-23
MX2023007181A (es) 2023-08-30
EP4263599A1 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
RU2760875C1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
JP2024075584A (ja) アミロイドベータタンパク質に対するモノクローナル抗体及びその使用
US20230192830A1 (en) Tau binding compounds
US20240059766A1 (en) Tau binding compounds
TW201900682A (zh) 抗ｐｈｆ－ｔａｕ抗體及其用途
US20250243263A1 (en) Tau binding compounds
JP7051150B2 (ja) 気分障害の治療及び診断のための抗－配列類似性１９を持つファミリー、メンバーａ５抗体の用途
BRPI0709050A2 (pt) anticorpo ou fragmento do mesmo, composição, métodos para prevenir ou tratar, e para diagnosticar distúrbios, métodos para detectar protofibrilas ab in vitro, e, uso do anticorpo
CN115260310A (zh) 抗补体因子c1q的fab片段及其应用
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
US20230151083A1 (en) Anti-phf-tau antibodies and uses thereof
JP2021515556A (ja) 抗ｐｈｆ−タウ抗体及びその使用
US20240150451A1 (en) Anti-tau antibodies and uses thereof
US12351623B2 (en) Antibody compositions targeting non-phosphorylated alpha-synuclein aggregates
JP2022528459A (ja) 融合構築物及びその使用
EA047298B1 (ru) Антитела к phf-тау и их применение
HK1140499B (en) Methods and compositions for diagnosis and treatment of amyloidosis
HK1140499A (en) Methods and compositions for diagnosis and treatment of amyloidosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104